The coexistence of several adverse factors such as ≥4 mitoses/10HPF, necrosis, Ki-67 ≥ 10%, mutations in HTER and/or p53 may suggest the need for a closer clinical follow-up regardless of the histological appearance of the tumor. This evidence concerns the gene MKI67 and neoplasm.